【又一款国产带状疱疹疫苗申报上市，中老年人的接种市场仍待撬开】金十数据2月10日讯，近日，绿竹生物发布了其重组带状疱疹疫苗LZ901上市申请获得国家药监局受理消息。如顺利上市的话，这款疫苗将成为在国内上市的第三款带状疱疹疫苗。目前已上市的两款带状疱疹疫苗，一款是国产疫苗，厂家是百克生物；一款是进口疫苗，厂家是葛兰素史克。带状疱疹是由长期潜伏在脊髓后根神经节或颅神经节内的水痘-带状疱疹病毒经再激活引起的感染性皮肤病。随着年龄的增长，人体生理代谢功能和免疫机能逐渐衰退，罹患带状疱疹这样的感染性疾病风险增加。接种带状疱疹疫苗是预防带状疱疹的有效措施。随着中国人口老龄化进程加快，带状疱疹疫苗市场被视为未来前景可观。不过，从已在国内上市的两款带状疱疹疫苗来看，当前要撬开中老年人的疫苗接种市场，仍然不容易。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.